{"analyses":[{"ciLowerLimit":"-0.015","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.046","groupDescription":"Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.3069","paramType":"Least Square Mean Difference","paramValue":"0.016","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"-0.013","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.05","groupDescription":"Cycle 6 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.2472","paramType":"Least Square Mean Difference","paramValue":"0.019","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"-0.021","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.044","groupDescription":"Cycle 9 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.4972","paramType":"Least Square Mean Difference","paramValue":"0.011","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"-0.004","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.062","groupDescription":"Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0841","paramType":"Least Square Mean Difference","paramValue":"0.029","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"-0.008","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.062","groupDescription":"Cycle 18 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.1296","paramType":"Least Square Mean Difference","paramValue":"0.027","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"-0.003","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.07","groupDescription":"Cycle 24 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0762","paramType":"Least Square Mean Difference","paramValue":"0.033","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"-0.025","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.052","groupDescription":"Cycle 30 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.4859","paramType":"Least Square Mean Difference","paramValue":"0.014","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"-0.029","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.051","groupDescription":"Cycle 36 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.6031","paramType":"Least Square Mean Difference","paramValue":"0.011","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"0.009","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.093","groupDescription":"Cycle 42 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0178","paramType":"Least Square Mean Difference","paramValue":"0.051","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"-0.038","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.053","groupDescription":"Cycle 48 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.7460","paramType":"Least Square Mean Difference","paramValue":"0.007","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"-0.012","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.086","groupDescription":"Cycle 54 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.1394","paramType":"Least Square Mean Difference","paramValue":"0.037","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"-0.045","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.068","groupDescription":"Cycle 60 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.6982","paramType":"Least Square Mean Difference","paramValue":"0.011","statisticalMethod":"Mixed Models Analysis"},{"ciLowerLimit":"-0.001","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.14","groupDescription":"Cycle 66 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0543","paramType":"Least Square Mean Difference","paramValue":"0.069","statisticalMethod":"Mixed Models Analysis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.058","upperLimit":"0.103","value":"0.081"},{"groupId":"OG001","lowerLimit":"0.074","upperLimit":"0.119","value":"0.097"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"302"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.087","upperLimit":"0.135","value":"0.111"},{"groupId":"OG001","lowerLimit":"0.107","upperLimit":"0.152","value":"0.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"287"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.088","upperLimit":"0.138","value":"0.113"},{"groupId":"OG001","lowerLimit":"0.101","upperLimit":"0.147","value":"0.124"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"267"}],"units":"Participants"}],"title":"Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.078","upperLimit":"0.128","value":"0.103"},{"groupId":"OG001","lowerLimit":"0.108","upperLimit":"0.155","value":"0.132"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.062","upperLimit":"0.116","value":"0.089"},{"groupId":"OG001","lowerLimit":"0.092","upperLimit":"0.14","value":"0.116"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"242"}],"units":"Participants"}],"title":"Cycle 18 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.059","upperLimit":"0.116","value":"0.088"},{"groupId":"OG001","lowerLimit":"0.096","upperLimit":"0.145","value":"0.121"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"227"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.058","upperLimit":"0.118","value":"0.088"},{"groupId":"OG001","lowerLimit":"0.076","upperLimit":"0.127","value":"0.102"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"198"}],"units":"Participants"}],"title":"Cycle 30 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.067","upperLimit":"0.131","value":"0.099"},{"groupId":"OG001","lowerLimit":"0.083","upperLimit":"0.135","value":"0.109"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"195"}],"units":"Participants"}],"title":"Cycle 36 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.028","upperLimit":"0.096","value":"0.062"},{"groupId":"OG001","lowerLimit":"0.086","upperLimit":"0.14","value":"0.113"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"178"}],"units":"Participants"}],"title":"Cycle 42 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.038","upperLimit":"0.112","value":"0.075"},{"groupId":"OG001","lowerLimit":"0.055","upperLimit":"0.11","value":"0.082"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"162"}],"units":"Participants"}],"title":"Cycle 48 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.01","upperLimit":"0.091","value":"0.05"},{"groupId":"OG001","lowerLimit":"0.058","upperLimit":"0.116","value":"0.087"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"141"}],"units":"Participants"}],"title":"Cycle 54 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.02","upperLimit":"0.115","value":"0.068"},{"groupId":"OG001","lowerLimit":"0.047","upperLimit":"0.111","value":"0.079"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"title":"Cycle 60 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.019","upperLimit":"0.102","value":"0.041"},{"groupId":"OG001","lowerLimit":"0.073","upperLimit":"0.148","value":"0.111"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"Cycle 66 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"302"}],"units":"Participants"}],"description":"EQ-5D-5L was standardized, participant-reported questionnaire to assess health-related quality of life. EQ-5D-5L included 2 components: EQ-5D-5L health state profile (descriptive system) and EQ-5D-5L VAS. EQ-5D-5L descriptive system provided a profile of participant's health state 5 dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflected increasing levels of difficulty. Participants indicated their health state by selecting the most appropriate level in each of the 5D. Responses to the 5D scores were combined and converted into single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of individual (but allows for values less than 0 by United kingdom scoring algorithm). Higher score indicated better health state.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Lenalidomide 25 milligrams (mg) capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously (IV) once a week (QW) until disease progression or unacceptable toxicity up to 77.5 months. After completion of treatment, participants entered follow-up phase and were not started on subsequent anti-myeloma therapy without confirmed disease progression (assessed by the International Myeloma Working Group \\[IMWG\\] criteria).","id":"OG000","title":"Lenalidomide + Dexamethasone (Rd)"},{"description":"Participants received Daratumumab 16 milligrams per kilograms (mg/kg) IV QW for the first 8 weeks (cycles 1-2) and then every 2 weeks (Q2W) for 16 weeks (Cycle 3-6), then every 4 weeks (Q4W) (from Cycle 7 and beyond) (each cycle of 28 days), Lenalidomide 25 mg capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or IV QW until disease progression or unacceptable toxicity up to 77.3 months. After implementation of Amendment 8, participants who were ongoing with daratumumab IV treatment were given an option to switch to daratumumab subcutaneous (SC) injection on Day 1 of any cycle, as per investigator's discretion. After completion of treatment, participants entered follow-up phase and were not started on subsequent anti-myeloma therapy without confirmed disease progression (assessed by IMWG criteria).","id":"OG001","title":"Daratumumab + Lenalidomide + Dexamethasone (DRd)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"ITT population included all randomized participants. Here 'N' (overall number of participants analyzed) signifies number of participants who were evaluable for this outcome measure; 'n' signifies number of participants analyzed at specified timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline (Day -24) and Day 1 of Cycles 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 and 66 (each Cycle of 28 days)","title":"Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Utility Score","type":"SECONDARY","unitOfMeasure":"Score on scale"}